Literature DB >> 16517129

Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists.

Lucia Carboni1, Miriam Vighini, Chiara Piubelli, Laura Castelletti, Alberto Milli, Enrico Domenici.   

Abstract

Chronic administration of antidepressants is required for their efficacy, suggesting the involvement of long-term modifications. As the impact of antidepressant treatment on the brain molecular machinery is not completely understood, we performed a proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine, with an NK1 receptor antagonist, GR205171, and a CRF receptor 1 antagonist, DMP696. After 2D electrophoresis, protein expression levels were compared with both univariate and multivariate statistical analyses and identified by mass spectrometry. All treatments modified levels of actin isoforms, whereas both fluoxetine and GR205171 reduced synapsin II. Fluoxetine treatment increased ERK2 and NP25 and decreased vacuolar ATP synthase. After GR205171 treatment, protein disulphide isomerase A was reduced; dynamin 1 and aldose reductase increased. DMP696 modulated DRP2, pyruvate kinase, LDH and ATP synthase. Although each compound induced a specific pattern of protein modulation, data suggest that antidepressants share the ability of modulating neural plasticity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517129     DOI: 10.1016/j.euroneuro.2006.01.007

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

Review 1.  Recent advances in neuroproteomics.

Authors:  Erika C Andrade; Dilja D Krueger; Angus C Nairn
Journal:  Curr Opin Mol Ther       Date:  2007-06

2.  Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2.

Authors:  Senem Merve Fred; Liina Laukkanen; Cecilia A Brunello; Liisa Vesa; Helka Göös; Iseline Cardon; Rafael Moliner; Tanja Maritzen; Markku Varjosalo; Plinio C Casarotto; Eero Castrén
Journal:  J Biol Chem       Date:  2019-10-20       Impact factor: 5.157

Review 3.  Transgelin-2: Biochemical and Clinical Implications in Cancer and Asthma.

Authors:  Lei-Miao Yin; Luis Ulloa; Yong-Qing Yang
Journal:  Trends Biochem Sci       Date:  2019-06-27       Impact factor: 13.807

4.  Elucidating novel mechanisms of brain injury following subarachnoid hemorrhage: an emerging role for neuroproteomics.

Authors:  Melanie D King; Melissa D Laird; Sangeetha Sukumari Ramesh; Patrick Youssef; Basheer Shakir; John R Vender; Cargill H Alleyne; Krishnan M Dhandapani
Journal:  Neurosurg Focus       Date:  2010-01       Impact factor: 4.047

5.  Fluoxetine increases plasticity and modulates the proteomic profile in the adult mouse visual cortex.

Authors:  L Ruiz-Perera; M Muniz; G Vierci; N Bornia; L Baroncelli; A Sale; F M Rossi
Journal:  Sci Rep       Date:  2015-07-24       Impact factor: 4.379

6.  Cytoskeletal protein translation and expression in the rat brain are stressor-dependent and region-specific.

Authors:  Petra Sántha; Magdolna Pákáski; Eszter K Fodor; Örsike Cs Fazekas; Sára Kálmán; János Kálmán; Zoltán Janka; Gyula Szabó; János Kálmán
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

7.  Synaptoproteomic analysis of a rat gene-environment model of depression reveals involvement of energy metabolism and cellular remodeling pathways.

Authors:  Alessandra Mallei; Marion Failler; Stefano Corna; Giorgio Racagni; Aleksander A Mathé; Maurizio Popoli
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

8.  Effects of CRMP2 DNA Methylation in the Hippocampus on Depressive-Like Behaviors and Cytoskeletal Proteins in Rats.

Authors:  Dan Xiang; Siqi Sun; Gaohua Wang; Zhongchun Liu
Journal:  Front Cell Neurosci       Date:  2021-03-17       Impact factor: 5.505

9.  Proteomic investigation of the ventral rat hippocampus links DRP-2 to escitalopram treatment resistance and SNAP to stress resilience in the chronic mild stress model of depression.

Authors:  Christina F Bisgaard; Magdalena N Jayatissa; Jan J Enghild; Connie Sanchéz; Roman Artemychyn; Ove Wiborg
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

10.  Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation.

Authors:  C Webhofer; P Gormanns; V Tolstikov; W Zieglgänsberger; I Sillaber; F Holsboer; C W Turck
Journal:  Transl Psychiatry       Date:  2011-12-13       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.